Small Cell Carcinoma and Lymphomas in Respiratory Specimens

Small cell carcinoma of the lung is a high-grade neuroendocrine malignancy with distinctive cytology, and its recognition has direct consequences because its management differs from non-small cell carcinoma. Cytologically it must be separated from non-small cell carcinoma and from lymphoid populations, a distinction that combines characteristic cytomorphology with immunocytochemical and, for lymphoma, flow-cytometric or molecular confirmation.

Definition

Small cell carcinoma is a high-grade neuroendocrine carcinoma of the lung defined cytologically by small cells with scant cytoplasm, finely granular nuclear chromatin, nuclear moulding, and brisk apoptosis and mitosis; lymphomas in respiratory specimens are clonal lymphoid proliferations recognised cytologically with the aid of immunophenotyping.

Scope

This topic covers the cytomorphology of small cell carcinoma, the features and ancillary studies that separate it from squamous and other non-small cell carcinomas, and the recognition of lymphoid populations and lymphoma in respiratory and associated effusion or nodal specimens. It is a reference-educational overview of cytologic recognition and confirmation, not a guide to staging or treatment.

Core questions

• Which cytologic features identify small cell carcinoma and separate it from non-small cell carcinoma?
• How is small cell carcinoma distinguished from a lymphoid population in respiratory specimens?
• What ancillary studies confirm small cell carcinoma versus lymphoma?

Key concepts

• Small cells with scant cytoplasm and high nuclear-to-cytoplasmic ratio
• Finely granular ('salt-and-pepper') chromatin and nuclear moulding
• Crush artefact, apoptosis, and high mitotic activity
• Neuroendocrine and proliferation immunomarkers
• Distinguishing small cell carcinoma from lymphoid populations
• Flow cytometry and clonality testing for lymphoma

Mechanisms

Small cell carcinoma exfoliates as loosely cohesive small cells with scant cytoplasm, a high nuclear-to-cytoplasmic ratio, finely granular chromatin, absent or inconspicuous nucleoli, and nuclear moulding, often with crush artefact, abundant apoptotic debris, and frequent mitoses. These features and supportive neuroendocrine and high-proliferation immunomarkers separate it from squamous cell and other non-small cell carcinomas (Gailey 2016). Because small, discohesive malignant cells can resemble a lymphoid infiltrate, distinguishing small cell carcinoma from lymphoma relies on immunophenotyping, with flow cytometry and clonality or molecular testing used to confirm a lymphoid neoplasm; epithelial and neuroendocrine markers confirm carcinoma.

Clinical relevance

Recognising small cell carcinoma and separating it from non-small cell carcinoma and from lymphoma is consequential because these diagnoses follow different management pathways, and cytologic specimens are frequently the diagnostic material in advanced disease. This entry describes the cytologic and ancillary distinctions for reference and does not provide staging or treatment recommendations for individual patients.

Epidemiology

Small cell carcinoma accounts for a minority of lung cancers but is clinically distinct as a high-grade neuroendocrine tumour within the 2021 WHO classification (Nicholson 2022); it is strongly associated with tobacco exposure.

Evidence & guidelines

Comparative cytologic and immunohistochemical study addresses the practical separation of small cell carcinoma from squamous cell carcinoma on cytologic specimens (Gailey 2016). The 2021 WHO classification defines small cell carcinoma among pulmonary neuroendocrine neoplasms (Nicholson 2022), and diagnostic guidance frames how cytologic material establishes a lung cancer diagnosis (Rivera 2013).

History

Small cell carcinoma was distinguished from other lung cancers in mid-twentieth-century classifications because of its distinctive behaviour, and its neuroendocrine nature and cytologic criteria were refined in successive WHO classifications, most recently in 2021 (Nicholson 2022). The growing reliance on small cytologic specimens has sharpened attention to immunocytochemical confirmation and to the distinction from lymphoid mimics (Gailey 2016).

Seminal works

• gailey-2016
• nicholson-2022

Frequently asked questions

What cytologic features suggest small cell carcinoma?

Small cells with very scant cytoplasm, a high nuclear-to-cytoplasmic ratio, finely granular chromatin, nuclear moulding, crush artefact, frequent apoptosis, and brisk mitotic activity are characteristic, supported by neuroendocrine and high-proliferation immunomarkers.

How is small cell carcinoma told apart from lymphoma in respiratory specimens?

Both can present as small discohesive cells, so immunophenotyping is used: epithelial and neuroendocrine markers support carcinoma, while lymphoid markers with flow cytometry or clonality testing support lymphoma.